Cardinal Health Expands Radiopharma Capacity Amid Valuation and Risk Concerns

What happened

Cardinal Health announced an expansion of its Actinium-225 production capacity to bolster its role in radiopharmaceuticals for cancer therapies, as reported by Zacks Investment Research. This move aligns with the company's strategic pivot toward higher-margin specialty segments, including nuclear and precision health solutions, which are part of its 'Other' segment detailed in the DeepValue master report. However, the report highlights that CAH's stock is overvalued at approximately $214, trading at 22x FY26 non-GAAP EPS, with significant risks from customer concentration (CVS at 30% of revenue) and rising debt from recent acquisitions. While the capacity expansion could support long-term growth in a promising oncology niche, it does not immediately address underlying issues such as the widening gap between GAAP and non-GAAP earnings or integration challenges from MSO platforms. Investors should view this development critically within the context of the investment thesis, which emphasizes limited margin of safety and crowded momentum ownership.

Implication

The Ac-225 capacity increase may enhance Cardinal's positioning in the radiopharma market, potentially driving incremental revenue from cancer therapies over time. However, given the company's elevated valuation multiples and reliance on non-GAAP adjustments, the financial impact is likely to be gradual and may not meaningfully improve GAAP earnings quality. The DeepValue report underscores persistent downsides, including customer concentration with CVS, policy risks from IRA drug pricing reforms, and rising interest expense, which could overshadow any near-term benefits from this expansion. Strategically, this move is consistent with management's focus on higher-margin growth businesses, but it adds to capital deployment without reducing leverage or addressing integration complexities from recent acquisitions. Consequently, investors should maintain a cautious stance, as this news does not alter the fundamental risk/reward profile that favors trimming exposure above certain price levels.

Thesis delta

The expansion of Ac-225 capacity is a tactical advancement within Cardinal's existing specialty growth strategy but does not materially shift the investment thesis. It reinforces the company's commitment to higher-margin segments, yet the core concerns—overvaluation, earnings quality issues, and concentration risks—remain unchanged. Therefore, no adjustment to the 'POTENTIAL SELL' rating is warranted; investors should continue to monitor execution and policy impacts as outlined in the DeepValue report.